BRISBANE'S WORLD-FIRST ASTHMA TREATMENT

BRISBANE'S WORLD-FIRST ASTHMA TREATMENT
ASTHMA sufferers: Brisbane drug development company Invion (ASX: IVX) has partnered with a global manufacturer to progress development of a novel asthma treatment.

The inhaled INV104 has been coined as a potential new treatment for asthma, which is estimated to afflict 300 million people worldwide.

The global market for asthma therapeutics is more than $22 billion per annum.

The compound already exists but is now being reformulated for inhalation. Hovione Scienta has collaborated with Invion to develop the proprietary novel technology, which is a dry powder formulation of the compound delivered by an inhaler.

Hovione will provide expertise on chemistry, particle engineering, formulation, device and GMP manufacturing, while IVX will oversee all non-clinical and clinical development, and remain responsible for regulatory submissions.

This trajectory for growth comes as IVX has received agreement from the FDA to proceed in accelerated development of the new formulation and device.

IVX CEO and managing director Greg Collier says, both medically and commercially, the new method is superior.

"We are reformulating this compound for inhalation and remain confident that delivering this compound directly into the lung in this manner will provide superior benefit and bypass any problems associated with systemic delivery," says Collier.

"Hovione is the right partner to help us capitalise on this highly promising commercial opportunity."


Get our daily business news

Sign up to our free email news updates.

 
Whitefox Recruitment founder Luke Hemmings making strides as a careers leader
Partner Content
After relocating his Canberra-founded company Whitefox Recruitment to the Gold Coast la...
Whitefox Recruitment
Advertisement

Related Stories

ASIC secures its first court win for greenwashing against US giant Vanguard

ASIC secures its first court win for greenwashing against US giant Vanguard

The Australian corporate watchdog has caught out one of the world&r...

Medicinal cannabis group Althea shaves $1.5m from its cost base through staff cutbacks

Medicinal cannabis group Althea shaves $1.5m from its cost base through staff cutbacks

Australian-founded medicinal cannabis company Althea Group (ASX: AG...

Charter Hall snares 15pc stake in Hotel Property Investments for $97m from 360 Capital

Charter Hall snares 15pc stake in Hotel Property Investments for $97m from 360 Capital

Listed funds manager 360 Capital Group (ASX: TGP) has offloaded its...

The party’s over: Splendour in the Grass festival cancelled for 2024

The party’s over: Splendour in the Grass festival cancelled for 2024

Splendour in the Grass, Australia’s largest winter music fest...